Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Zentalis Pharmaceuticals, Inc. | Chief Medical Officer | Common Stock | 36.6K | $83.6K | $2.28 | Feb 6, 2025 | Direct |
Zentalis Pharmaceuticals, Inc. | Chief Medical Officer | Stock Option (Right to Buy) | 16.6K | Feb 3, 2025 | Direct | ||
Trillium Therapeutics Inc. | Chief Medical Officer | Stock Option (Right to Buy) | 0 | Nov 17, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ZNTL | Zentalis Pharmaceuticals, Inc. | Feb 6, 2025 | 1 | $45.7K | 4 | Feb 12, 2025 | Chief Medical Officer |
ZNTL | Zentalis Pharmaceuticals, Inc. | Feb 3, 2025 | 2 | $0 | 4 | Feb 5, 2025 | Chief Medical Officer |
ZNTL | Zentalis Pharmaceuticals, Inc. | Dec 2, 2024 | 1 | $0 | 4 | Dec 3, 2024 | Chief Medical Officer |
ZNTL | Zentalis Pharmaceuticals, Inc. | Nov 13, 2024 | 0 | $0 | 3 | Nov 13, 2024 | Chief Medical Officer |
TRIL | Trillium Therapeutics Inc. | Nov 17, 2021 | 1 | $0 | 4 | Nov 19, 2021 | Chief Medical Officer |